prostate cancer

Latest Headlines

Latest Headlines

Myriad inks coverage deal for prostate cancer test

Myriad Genetics has inked a three-year contract with Tufts Health Plan to provide its Prolaris biopsy test for members diagnosed with localized prostate cancer.

Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive

Private equity group Essex Woodlands has snapped up a 16% stake in surgical peripheral nerve solutions company AxoGen. The company raised $17.5 million to back its existing regenerative medicine products, as well as to develop new candidates for nerves severed during prostate cancer surgery and lower extremity nerve injuries. The financing is expected to put the company in the black for the first time.

Myriad snags Medicare coverage for prostate cancer test

Myriad Genetics nabbed Medicare coverage for its prostate cancer screening test, a win for the company as it struggles with waning revenues and increased competition from rivals in the genetic testing market.

Xtandi marketer Astellas scrums with rugby partners for prostate cancer awareness

Astellas is partnering with both USA Rugby and the Australia Rugby Union for a new prostate cancer campaign. Though it's an unbranded push, the "Pass4Prostate" promotion fits right in with Astellas' stepped-up marketing of Xtandi, the prostate cancer med now approved for previously untreated patients.

Bavarian Nordic starts PhII of Prostvac in early-stage cancer

Looking to expand its potential market for prostate cancer immunotherapy candidate Prostvac, Bavarian Nordic has announced that it's beginning a Phase II trial for its vaccine in early-stage prostate cancer, representing another possible avenue to broaden the candidate's reach.

UCLA researchers position glucose transporter as a target for pancreatic, prostate cancer

Promising research conducted by Dr. Ernest Wright and Dr. Jorge Barrio, both of UCLA's Jonsson Comprehensive Cancer Center, show two types of sodium-dependent glucose transports known as SGLT1 and SGLT2 are actively involved in glucose uptake into tumors. And that makes them prime targets for drug investigators.

Profound Medical partners with Philips just after reverse merger

Profound Medical went public on the Toronto Stock Exchange last month and raised $25 million in June. Now, it's partnered with Royal Philips to develop its novel, minimally invasive prostate gland ablation tool to be used on Philips' MRI systems.

Glucose delivery pathway that feeds tumors could be exploited to knock them down

New work from researchers at UCLA is shedding light on the delivery of glucose to tumor cells, particularly in pancreatic and prostate cancers. The research could offer new diagnostic procedures for detecting these cancers and, down the road, the use of inhibitors to cut down the amount of glucose delivered to the tumors, slowing down their growth.

Experimental prostate cancer combo shows promise in case studies

Dr. Matthias Eder of the German Cancer Research Center has been working on a new molecule that targets prostate-specific membrane antigen, a protein that clusters on the surface of prostate cancer cells.

Augmenix unleashes promising data for injectable prostate cancer spacer

Augmenix is trumpeting results from a study of its prostate cancer spacing device, promising data as the company charges ahead with development for the product after snagging FDA clearance in April.